Clinical Trials
8 trialsNCT04196933 2025-04-16
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
Massachusetts Eye and Ear Infirmary
Phase NA Withdrawn
NCT06929468 2025-04-16
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
Paracelsus Medical University
Not yet recruiting
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT04859335 2024-08-02
EQUI-GAMMA
University Hospital, Toulouse
Phase NA Recruiting
NCT04890132 2023-03-16
Vestibular Precision: Physiology & Pathophysiology
Massachusetts Eye and Ear Infirmary
Phase NA Unknown
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT03639415 2021-03-08
Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Fujian Cancer Hospital
Phase 4 Withdrawn
NCT03670589 2018-09-13
EVTSVCGEC
University Hospital, Grenoble
Completed